Capricor Therapeutics, Inc. (CAPR) vs DiaMedica Therapeutics Inc. (DMAC)
A side-by-side comparison of Capricor Therapeutics, Inc. and DiaMedica Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CAPR
Capricor Therapeutics, Inc.
$7.56HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
DMAC
DiaMedica Therapeutics Inc.
$8.50HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT
Total return — CAPR vs DMAC
growth of $100 · dividends reinvested · last 10yCAPR -76.9% (-13.6%/yr)DMAC +113.7% (+7.9%/yr)DMAC compounded faster over this window
Log scale — wide-divergence pair
CAPR DMAC
CAPR vs DMAC: by the numbers
- •DMAC is the larger company ($458M vs $435M market cap).
Metrics side by side
Valuation
| Metric | CAPR | DMAC |
|---|---|---|
| P/B ratio | 1.77 | 11.94 |
| EV / EBITDA | 0.43 | N/A |
Profitability
| Metric | CAPR | DMAC |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -52.56% | -97.92% |
| ROIC | -40.25% | -100.87% |
Growth (annualized)
| Metric | CAPR | DMAC |
|---|---|---|
| Total return CAGR (5Y) | 15.17% | 16.41% |
Frequently asked
- How have CAPR and DMAC total returns compared?
- Over the past 10 years, CAPR delivered -13.84% and DMAC delivered 7.89% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.